Joseph Binder

Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19

Britton Boras, Rhys Jones, Brandon J. Anson et al. · Nature Communications · 2021 · 296 citations · Full text

Pharmacy, Infectious Diseases, Pharmacology +15

Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19

Britton Boras, Rhys Jones, Brandon J. Anson et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2020 · 159 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

A Comparative Analysis of SARS-CoV-2 Antivirals Characterizes 3CL ^pro Inhibitor PF-00835231 as a Potential New Treatment for COVID-19

Maren de Vries, Adil Mohamed, Rachel A. Prescott et al. · Journal of Virology · 2021 · 142 citations · Full text

Medicine, Infectious Diseases, Pharmacology +15

A comparative analysis of SARS-CoV-2 antivirals in human airway models characterizes 3CL ^pro inhibitor PF-00835231 as a potential new treatment for COVID-19

Maren de Vries, Adil Mohamed, Rachel A. Prescott et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2020 · 24 citations · Full text

Medicine, Infectious Diseases, Pharmacology +16

Oncolytic Vaccinia Virus Gene Modification and Cytokine Expression Effects on Tumor Infection, Immune Response, and Killing

Tomoyoshi Inoue, Thomas Byrne, Mitsuko Inoue et al. · Molecular Cancer Therapeutics · 2021 · 17 citations · Full text

Life Sciences, Immunology, Oncology +17